Skip to main content
Skip to main content
Sellas Life Sciences
Sellas Life Sciences
  • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Contact Us
  • Pipeline
    • Indications
  • Science
    • Galinpepimut-S: WT1 Targeting Immunotherapeutic
    • SLS009: Highly Selective CDK9 Inhibitor
    • Publications
  • Clinical Trials
    • Ongoing
    • Completed
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources
  • Careers

WT1 Antigen ranked by National Cancer Institute as a top priority for immunotherapy

Learn More

Contact

  • Home
    • Overview
    • Company
      • About SELLAS
      • Management
      • Board of Directors
      • Scientific Advisory Board
      • Partnerships
      • Contact
    • Sellas Pipeline
      • Indications
    • Galinpepimut-S (GPS) Therapy
      • Our Therapy
      • Wt1 Cancer Immunotherapy
      • Wt1 Immunotherapy Development
    • News
    • Pipeline
      • NELIPEPIMUT-S (NPS) Clincal Trials
      • Anagrelide CR Clinical Trials
    • Events & Presentations
    • Publications
      • Galinpepimut-S (GPS)
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Indications
    • Analyst Coverage
    • Financials
    • Investors
      • Media Coverage
    • SEC Filings
    • Corporate Governance
      • Management
      • Board of Directors
      • Governance Documents
      • Committee Composition
      • Board Diversity Matrix
    • Investor Resources
      • Contact IR
      • Investor FAQs
      • Whistleblower
      • Information Request
      • Email Alerts
      • Derivative Litigation
    • Careers
    • Shareholder Letter

Contact US

646-200-5278 sellas@lifesci.com

Address

Headquarters: United States of America

Times Square Tower, 7 Times Square, Suite 2503, New York, NY 10036
646-200-5278

Send Message

    Name*
     
    Email Address*
     
    Message*
     
    Captcha text before
     
    Enter the code shown above.
     
    Sellas Life Sciences

    7 Times Square, Suite 2503
    New York, NY 10036
    646-200-5278

    info@sellaslife.com
    • Company
    • About SELLAS
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Contact Us
    • Pipeline
    • Indications
    • Science
    • Galinpepimut-S: WT1 Targeting Immunotherapeutic
    • SLS009: Highly Selective CDK9 Inhibitor
    • Publications
    • Clinical Trials
    • Ongoing
    • Completed
    • Investors
    • Careers
    • Privacy Policy
    • Terms
    • Sitemap
    © SELLAS Life Sciences Group Inc. All Rights Reserved